Baudax Bio, Inc. (BXRXQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBaudax Bio, Inc. (BXRXQ) trades at $0.0001. Baudax Bio, Inc. is a biotechnology company focused on developing and commercializing products for acute care settings. The company filed for Chapter 11 reorganization in February 2024. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for BXRXQ: BXRXQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Baudax Bio, Inc. (BXRXQ) Healthcare & Pipeline Overview
Baudax Bio, Inc. is a biotechnology firm specializing in therapies for acute care, including neuromuscular blocking agents and reversal agents. Currently under Chapter 11 reorganization, the company's pipeline includes BX1000 (Phase II), BX2000 (Phase I), and BX3000 (preclinical), targeting unmet needs in hospital settings. The company faces significant financial and operational challenges.
What Is the Investment Thesis for BXRXQ?
Investing in Baudax Bio (BXRXQ) presents a highly speculative opportunity due to the company's Chapter 11 reorganization. The potential value lies in the successful restructuring and advancement of its pipeline assets, particularly BX1000, BX2000, and BX3000. Positive clinical trial results could drive significant value, but the company faces substantial financial hurdles. With a market capitalization of $0.00B and negative free cash flow, BXRXQ's high beta of 27.02 reflects its extreme volatility. Investors should carefully consider the risks associated with bankruptcy and the uncertainty surrounding the company's future operations. The company's ability to secure additional funding and navigate the regulatory landscape will be critical to its long-term success.
Based on FMP financials and quantitative analysis
BXRXQ Key Highlights
Baudax Bio filed for Chapter 11 bankruptcy on February 22, 2024, indicating severe financial distress.
- The company's lead product candidate, BX1000, is in Phase II clinical trials, targeting intermediate-acting neuromuscular blockade.
- BX2000, an ultra-short acting NMB, is in Phase I clinical trials, representing an earlier-stage asset.
- BX3000, a NMB reversal agent, is in preclinical development, highlighting potential future pipeline expansion.
- The company has a market capitalization of $0.00B, reflecting its distressed financial state.
Who Are BXRXQ's Competitors?
BXRXQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.90 | -1.05% | $89.7M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | +1.34% | $186M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.75% | $202M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.68 | -3.94% | $213M | 68 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | 0.00% | $218M | 73 5-pillar |
| QTTB Q32 Bio Inc. | $8.37 | +1.70% | $249M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.27 | +1.17% | $571M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BXRXQ's Key Strengths?
Pipeline of novel neuromuscular blocking agents and reversal agents.
- Focus on unmet needs in acute care settings.
- Proprietary drug formulations.
- Experienced management team (prior to Chapter 11).
What Are BXRXQ's Weaknesses?
Chapter 11 bankruptcy filing.
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
- High regulatory risk.
What Are the Key Risks for BXRXQ?
Financial-distress signal — its Altman Z-Score of -17.42 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Chapter 11 bankruptcy poses a significant risk to shareholders.
- Clinical trial failures could derail product development.
- Regulatory setbacks could delay or prevent product approvals.
- Inability to secure additional funding could hinder operations.
- Competition from established pharmaceutical companies.
What Are BXRXQ's Competitive Advantages?
- Proprietary drug formulations.
- Patent protection for pipeline assets.
- Specialized expertise in neuromuscular blocking agents and reversal agents.
- First-mover advantage in specific niche markets.
What Does BXRXQ Do?
Baudax Bio, Inc. is a biotechnology company dedicated to developing and commercializing innovative products for hospital and acute care environments. Founded in 2015 and based in Malvern, Pennsylvania, the company focuses on addressing critical unmet needs in anesthesia and critical care. Baudax Bio's pipeline includes neuromuscular blocking agents (NMBs) and reversal agents. Their lead product candidates include BX1000, an intermediate-acting NMB in Phase II clinical trials, BX2000, an ultra-short acting NMB in Phase I clinical trials, and BX3000, a NMB reversal agent in preclinical development. These products aim to improve patient outcomes and streamline medical procedures in acute care settings. However, on February 22, 2024, Baudax Bio filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania, indicating significant financial distress. The company's future hinges on successful restructuring and the advancement of its clinical programs.
What Products and Services Does BXRXQ Offer?
- Develops T cell receptor therapies targeting immune modulation for orphan diseases and autoimmune disorders.
- Creates BX1000, an intermediate-acting neuromuscular blocking agent (NMB) currently in Phase II clinical trials.
- Develops BX2000, an ultra-short acting NMB in Phase I clinical trials, along with a proprietary blockade reversal agent.
- Works on BX3000, a NMB reversal agent in preclinical studies.
- Aims to commercialize products for hospital and other acute care settings.
- Focuses on improving patient outcomes and streamlining medical procedures in acute care.
How Does BXRXQ Make Money?
- Develops and patents novel pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Aims to commercialize approved products directly or through partnerships.
What Industry Does BXRXQ Operate In?
Baudax Bio operates within the biotechnology industry, which is characterized by high risk and high reward. The development of new drugs and therapies requires significant capital investment and faces regulatory hurdles. The market for neuromuscular blocking agents and reversal agents is competitive, with established players and emerging companies vying for market share. Baudax Bio's success depends on its ability to differentiate its products, navigate the regulatory landscape, and secure funding. The company's Chapter 11 filing underscores the challenges faced by small biotechnology companies in a capital-intensive industry.
Who Are BXRXQ's Key Customers?
- Hospitals and acute care facilities.
- Anesthesiologists and critical care physicians.
- Patients requiring neuromuscular blockade during surgical procedures.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Baudax Bio, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.42 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Baudax Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Gerri Henwood. BXRXQ has traded publicly since 2019.
Earnings Track Record
Baudax Bio, Inc. has beaten Wall Street's EPS estimate in 4 of its last 5 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 28.0% above estimates on average.
Forward Outlook
Wall Street analysts project Baudax Bio, Inc. revenue of about $35.2M for fiscal 2026, with EPS near $-0.05.
BXRXQ Financials
BXRXQ Latest News
No recent news available for BXRXQ.
BXRXQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BXRXQ.
Price Targets
Wall Street price target analysis for BXRXQ.
BXRXQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BXRXQ; grades run from A+ (80-100) to F (below 30).
BXRXQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Baudax Bio may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, are in financial distress, or may not be current in their reporting obligations. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Potential for fraud or manipulation.
- Low liquidity and high volatility.
- Going concern risk due to bankruptcy.
- Lack of regulatory oversight.
- Verify the company's legal status and registration.
- Review available financial statements, if any.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Consult with a financial advisor or legal professional.
- Research any potential red flags or warning signs.
- Company was incorporated in 2015.
- Focus on developing pharmaceutical products.
- Has pipeline assets in clinical trials.
- Headquartered in Malvern, Pennsylvania.
Baudax Bio, Inc. Healthcare Stock: Key Questions Answered
What is Baudax Bio, Inc.'s drug pipeline status?
Baudax Bio's drug pipeline includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) in Phase II clinical trials; BX2000, an ultra-short acting NMB in Phase I clinical trials, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited data available due to the company's OTC listing and Chapter 11 status.
- Analyst opinions and ratings may not be current or available.
- Forward-looking statements are subject to significant uncertainty.